The authors describe a novel drug strategy designed as a primary screen to discover either antagonist or agonist compounds targeting G-protein-coupled receptors (GPCRs). The incorporation of a nuclear localization sequence (NLS, a 5 amino acid substitution), in a location in helix 8 of the GPCR structure, resulted in ligand-independent receptor translocation from the cell surface to the nucleus. Blockade of the GPCR-NLS translocation from the cell surface was achieved by either antagonist or agonist treatments, each achieving their result in a sensitive concentration-dependent manner. GPCR-NLS translocation and blockade occurred regardless of the identity of the G-protein-coupling, and thus this assay is also ideally suited for identification of compounds targeting orphan GPCRs. The GPCR-NLS trafficking was visualized by fusion to fluorescent detectable proteins. Quantification of this effect was measured by determining the density of cell surface receptors, using enzyme fragment complementation in a manner suitable for high-throughput screening. Thus, the authors have developed a cellular assay for GPCRs suitable for compound screening without requiring prior identification of an agonist or knowledge of G-protein-coupling. (Journal of Biomolecular Screening 2007:175-185) 
INTRODUCTION
D UE TO PREVIOUS EFFORTS BY OUR GROUP and others, 1, 2 genes encoding the entire mammalian G-protein-coupled receptor (GPCR) family have been discovered. 3 The legacy of the cloning era has been the discovery of an abundance of receptors, consisting of new receptor/ligand systems, unanticipated subtypes for known receptors, and orphan receptors (oGPCRs) for which ligands are not known (reviewed in Howard et al. 2 and Marchese et al. 4 ). GPCRs regulate wide spectra of physiological functions, 5 features that make these receptors significant and attractive targets for drug discovery. An estimated ~50% of the current drug market now targets these GPCRs. 6, 7 Of the estimated ~367 nonodorant GPCRs, presently only ~30 GPCRs have been targeted by drugs, and thus the lucrative commercial potential of the vast majority of GPCRs has never been realized. 7, 8 There are unmet needs in GPCR drug discovery, including improved ways of assaying for compounds targeting oGPCRs, the need to obtain selective drugs at receptor subtype targets, and the need to obtain selective drugs at receptor heterooligomers. 8, 9 Of the methods available to screen for compounds targeting GPCRs, many require prior identification of an agonist to recognize antagonists or have requirements for a specific G-protein coupling to generate a signal. Thus, an assay independent of the G-protein coupled to the receptor would be an advantage, and the ability to screen simultaneously for agonists or antagonists would be of benefit. Thus, we addressed the need to overcome current assay deficiencies, and we generated a universal methodology to expedite GPCR drug discovery.
The strategy employed here harnessed the cellular mechanism for protein transport to the nucleus, and this pathway was adapted for the identification of compounds. Protein translocation to the nucleus involves importins that bind proteins containing a nuclear localization sequence (NLS). 10 We and others have previously described 1 GPCR that trafficked to the nucleus using an endogenous NLS located in helix 8. [11] [12] [13] Subsequently, we demonstrated that incorporating this NLS into helix 8 of GPCRs that do not contain an endogenous NLS mediated ligand-independent receptor translocation to the nucleus from the cell surface. 14 
Placement
of the NLS in helix 8 of the GPCR, in comparison to other locations within the intracellular loops and carboxyl tail, was shown to be critical for the receptor conformation sensitivity demonstrated. 14 By placement of the NLS in this receptor conformationdependent site, the GPCR-NLS translocation pathway could be exploited to identify interacting compounds, which, when bound to the receptor, had the capability of preventing the GPCR-NLS movement off the cell surface. 14 We show using a stably expressed D1 dopamine receptor-NLS that these receptors were redistributed from the cell surface to the cytoplasm and nucleus, and this translocation was prevented by specific ligand interaction. We also describe, in a format for primary drug screening, the integration of the GPCR-NLS translocation assay with enzyme fragment complementation (EFC) technology 15 to create a high-throughput screening (HTS) assay, in which drug effects of the GPCRs were comparable to radio ligand-binding affinities. We show that this cell-based assay appears universally effective as a primary screen for both antagonists and agonists targeting family A (rhodopsin-like) GPCRs. We predict that this method will be particularly useful for the identification of ligands targeting orphan GPCRs.
METHODS AND MATERIALS

Cell culture
Human embryonic kidney (HEK) cells grown on 60-mm plates in minimum essential medium (MEM) were transfected with 0.5 to 2 µg cDNA using lipofectamine (Life Technologies, Rockville, MD). Antagonists or agonists were added to cells at 6, 22, 30, and 42 h, and cells were visualized by confocal microscopy at 48 h posttransfection.
Microscopy
Live cells expressing D1-GFP and D1-GFP-NLS fusion protein were visualized with a LSM510 Zeiss confocal laser microscope. In each experiment, 5 to 8 fields, containing 50 to 80 cells per field, were evaluated, and the entire experiment was repeated 2 to 4 times (n = 3-5).
PCR conditions for DNA constructs
For each of the constructs, the PCR conditions were as previously reported. 14 
Prolabel receptor constructs
Generation of the Prolabel-TH-GPCR-NLS constructs was facilitated by the use of DiscoveRx's mammalian expression vector pCMV-Prolabel-N1, used for generating N-terminal Prolabel fusion proteins. To insert the thrombin cleavage sites, an XhoI/BamHI DNA fragment encoding the cleavage site (TH), followed by each GPCR-NLS DNA, was subcloned into the XhoI/BamHI sites of pCMV-Prolabel-N1, creating a fusion of Prolabel-TH-GPCR-NLS. The position of the NLS incorporated in helix 8 was as described. 14 The TH-GPCR-NLS DNA fragment was obtained by PCR amplification from each GPCR-NLS DNA template using PCR primers that introduce an XhoI site, TH epitope sequences at the 5´ end, and a BamHI site at the 3é nd. Each construct was subjected to DNA sequencing to confirm that appropriate mutagenesis occurred. When the constructs were generated, the mutagenesis was confirmed.
The construction of the D1-GFP and D1-NLS-GFP constructs was as described previously. 14 
GPCR-NLS EFC assay
Hekt cells were plated in 60-mm dishes and incubated for 24 h at 37 °C. The cells were transfected with Prolabel-GPCR or Prolabel GPCR-NLS using lipofectamine. The DNA was mixed with lipofectamine and incubated for 30 min at room temperature. The cells were exposed to this complex in MEM (no fetal bovine serum [FBS]) for 5 h. The medium was replaced with regular MEM (with FBS). For drug treatment, drug is added to the medium with the desired concentration. The transfected cells incubated at 37 °C overnight. The 96-well plate was coated with poly-L-ornithine. The cells were trypsinized and counted and plated with 50,000 cells per well in 250 µL media in the 96-well plate. For drug-treated cells, the cells were constantly exposed to the drug. The cells were incubated in the plate at 37 °C overnight. The medium was replaced with fresh medium, and the cells were incubated for another 24 h. Thrombin solution consisted of the following: 20 U/mL thrombin, 1× phosphate-buffered saline (PBS), 0.1 mg/mL bovine serum albumin (BSA), 10 mM each KF and Na azide, and 1 µM antagonist drug. The medium was removed and 50 µL/well thrombin solution added. The plate was incubated at 37 °C for 1.5 h. For the enzyme acceptor (EA) solution (DiscoveRx, Freemont, CA, reference #93-0180), 1 part EA reagent was mixed with 3 parts 1× PBS (1.83 mM MgSO 4 ; 10 mM each KF and Na azide). The EA solution (80 µL) was added and mixed by tapping gently and incubated at 37 °C for 1 h. The substrate solution (CL) was prepared by mixing 1 part Galacton-star ® , 5 parts Emerald II, and 19 parts substrate diluent (DiscoveRx). The CL was added (30 µL/well) and incubated at room temperature, protected from light. The luminescence was read by the Victor 1420 Multilabel Counter (PerkinElmer, Wellesley, MA) at periodic intervals from 15 min to 1 h.
Preparation of stable D1-NLS-GFP cell line
HEK cells were plated in 60-mm dishes and transfected with D1-NLS GFP (2 µg/plate) and incubated for 48 h. The cells were trypsinized and resuspended in G418 (1 mg/mL), and 200 µL of this suspension was added to 10-cm dishes. The colonies were picked and plated in 24-well plates. The cells were passaged in 6-well plates to reach confluency, plated in 60-mm dishes, and checked using the confocal microscope.
Drug replacement experiment
The cells were transfected with PL-D1-NLS and treated with 500 nM (+)-butaclamol ((+)BTC) for 24 h. The (+)BTC was removed by washing with PBS 3 times, fresh media were added with increasing incremental concentrations of dopamine, and the cells were transferred to the 96-well plate.
RESULTS
The dopamine D1 receptor was selected as the prototype GPCR with which to initiate and investigate the development of the assay strategy. In a previous report, we had described that the preferred placement of the NLS was in helix 8 of the GPCR because in this location, maximal conformation-dependent effects of ligand occupancy to retard translocation to the nucleus were demonstrated. 14 All of the GPCR-NLS constructs now described have the NLS in an equivalent location in helix 8.
Effect of antagonists on the cellular distribution of stably expressed D1-NLS
When cells stably expressing the D1 receptor tagged with GFP (D1-GFP) were visualized by confocal microscopy, the receptor was localized on the cell surface, whereas D1-NLS-GFP in stably expressing cells was visualized as distributed in the cytoplasm and nucleus, with minimal cell surface receptor expression ( Fig. 1A, left panel ). An antagonist concentration dependence with SCH 23390 was established using concentrations ranging from 10 nM to 1 µM (for 24 to 48 h). Differences in receptor distribution compared to no treatment were apparent at 10 nM, and the full effect of the majority of D1-NLS retained at the cell surface was achieved between 50 and 100 nM ( Fig. 1A , right panel). This pattern remained stable for more than 48 h. Cells expressing D1-NLS were also treated with varying doses of the antagonist (+)BTC showing very similar effects (1 concentration is shown in Fig. 1B, left panel) . The specificity of this effect was established by treatment of the D1-NLS-expressing cells with the β-adrenergic receptor antagonists atenolol and propranolol, as well as the D2 dopamine receptor antagonist raclopride, with which no effect on the distribution of the D1 receptor was observed ( Fig. 1B) . Stereoselectivity for this drug effect on D1-NLS was demonstrated by the lack of effect with (-)-butaclamol ((-)BTC) (1 µM, Fig. 1C, right panel) . Thus, treatment with D1 dopamine receptor antagonists efficiently prevented, in a dose-responsive manner with nanomolar effectiveness, the translocation of the D1-NLS receptor from the cell surface.
Following treatment of the D1-NLS-GFP-expressing cells, from 1 to 5 h, with the dopamine receptor agonist SKF 81297 (1 µM), the distribution expression pattern of D1-NLS was altered ( Fig. 1D) . At the earliest time of 1 h, there was a noticeable increase in cell surface D1-NLS distribution compared to no treatment; the full effect of the majority of the receptor being at the cell surface was apparent at 4 and 5 h.
Quantification of D1-NLS cell surface retention
To quantify the density of receptors at the cell surface, an EFC method (developed by DiscoveRx) was employed, involving complementation of 2 inactive fragments-named Prolabel (PL) and EA of β-galactosidase (β-gal)-making the enzyme capable of hydrolyzing a substrate to produce a chemiluminescent signal. 15, 16 The small PL fragment (4 KDa) was fused to the amino terminus of the D1-NLS receptor. An estimate of D1-NLS density at the cell surface was obtained by cleaving PL from the receptor with thrombin, followed by its interaction with EA. The use of PL does not affect GPCR pharmacology. 15, 16 GPCR detection was achieved in 96-well plates, and the luminescence signals were detected using the PerkinElmer Victor3 instrument.
To determine the optimal thrombin incubation time, the PL-D1-NLS receptor was expressed in the HEK cell lines for 24 h in the presence of (+)BTC to maximally retain the receptor at the cell surface. These cells were incubated with thrombin at 15, 30, 60, and 90 min at 37 °C, and it was determined that 90 min were required for a substantial effect of release of PL from the receptor. Cell surface receptor at 90 min was measured as 2.5-fold higher compared with a 15-min thrombin incubation ( Fig. 2A) .
Ligand-Induced Conformational Change to Screen GPCRs
Evidence that D1-NLS translocates rapidly from the cell surface
Cells transiently expressing PL-D1-NLS receptors were treated with the dopamine receptor antagonist (+)BTC (1 µM for 24 h). After exposure to (+)BTC for 24 h, the drug was removed, and the cells were incubated for 90 min at 37 °C. After this period of time, there was no retention of receptor at the cell surface, indicating that, in the absence of drug, the D1-NLS receptor translocated from the cell surface ( Fig. 2A) .
Concanavalin A treatment of cells expressing PL-D1-NLS
To investigate the cellular route by which PL-D1-NLS trafficked prior to translocating to the nucleus, cells expressing PL-D1-NLS were treated with concanavalin A (Con A; 0.25 mg/mL for 24 h) to retard translocation of the receptor from the cell surface. Following Con A treatment, the density of PL-D1-NLS was measured at the cell surface. There was a 4-fold increase in the cell surface receptor compared to no treatment, demonstrating that the receptor trafficked to the cell surface prior to translocating to the nucleus (Fig. 2B) . Thus, because the receptor is trafficked to the cell surface, it would be available to interact with compounds that were not cell permeable, making the assay suitable for all types of compounds. When the Con A-treated cells were also treated with (+)BTC (100 or 500 nM), there was a maximum ~8-fold increase in cell surface receptor density compared to no treatment. Thus, in addition to the receptor retained at the cell surface by Con A, the antagonist recruited significant additional receptor to the cell surface.
D1-NLS cell surface retention by antagonists
A concentration-dependent effect of SCH 23390 (concentrations from 0.01 nM to 10 µM), to retain the PL-D1-NLS receptor on the cell surface, indicated that the concentrations effectively prevented PL-D1-NLS from leaving the cell surface (Fig. 2C) .
There was a robust increase in cell surface receptor density response with increasing concentrations of the drug. At 5 µM concentration, there was a maximal 8-fold increase in cell surface receptor compared with no drug treatment, whereas there was a 7fold increase at 1 µM and a 5.2-fold increase at 50 nM compared with no treatment. The overall standards of the mean were small.
A concentration-dependent effect of (+)BTC to retain the PL-D1-NLS receptor on the cell surface was obtained (Fig. 2D) .
Here, the maximum effect of the drug retained was observed at ~5 µM, where there was a significant 11.6-fold increase in cell surface density of the receptor compared with no drug treatment, and at 1 µM, there was an 11.2-fold increase.
Quantification of D1-NLS cell surface retention by agonists
The concentration-dependent effect of dopamine (from 0.01 nM to 10 µM) retaining cell surface PL-D1-NLS receptor indicated that a maximum effect was obtained with 5 µM (15.5-fold), and at 1 µM, there was a 13-fold increase compared to no treatment ( Fig. 2E) . The D1 receptor agonist SKF 81297 also retained cell surface PL-D1-NLS receptor in a concentrationdependent manner (Fig. 2F) . At 5 µM, there was a 15-fold increase compared to no drug treatment, whereas at 1 µM treatment with the agonist, there was a 14.5-fold increase in cell surface compared to no drug treatment.
Replacement of drugs retaining D1-NLS at the cell surface
To perform assay validation for cell-impermeable compounds, cells expressing PL-D1-NLS receptors were treated first with (+)BTC (500 nM, for 48 h) to recruit and retain robust amounts of receptor at the cell surface. (+)BTC was removed and substituted immediately with dopamine ( Fig. 3) . A concentrationdependent effect of dopamine to retain the PL-D1-NLS receptor on the cell surface after (+)BTC removal was apparent; at a concentration of 1 µM dopamine, there was a 9.5-fold greater retention, and at 10 nM, it was 8.6-fold compared to no treatment (Fig. 3) . Thus, the confirmation induced by the antagonist (+)BTC occluding the NLS on the receptor is likely similar to that induced by the agonist. Similarly, a concentration-dependent effect of SKF 81297 after (+)BTC removal (from 1-100 nM) showed that this agonist retained the PL-D1-NLS receptor on the cell surface; at 100 nM, there was a ~3-fold increase compared to no treatment.
Cell surface retention by 6 additional GPCRs by either antagonists or agonists
To illustrate the universality of the assay, we made the small modification in the structures of 6 additional GPCRs by inserting an NLS in helix 8. In each case, the cell surface receptor was quantified by the EFC methodology.
D5 dopamine receptor.
Retention of the modified D5 dopamine receptor, D5-NLS, at the cell surface demonstrated the effective concentrations of SCH 23390 (Fig. 4A) . A maximum effect at 5 µM showed a 15-fold increase, a 14-fold increase at 1 µM, and an 8.5-fold increase at 50 nM in cell surface receptor density. Retention of cell surface D5-NLS also demonstrated the effective concentrations of (+)BTC (Fig. 4B) . A maximum effect at 5 µM showed a 16-fold increase, and at 1 µM, there was a 13.3fold increase in cell surface receptor density. A concentration-dependent effect of dopamine treatments indicated the most effective agonist concentrations (Fig. 4C) . There was a 10.5-fold increase at 5 µM, a 9-fold increase at 1 µM, and an 8.5-fold increase at 500 nM in cell surface receptor compared to no drug treatment. With agonist SKF 81297 at 1 µM, there was a 4.0-fold increase in cell surface expression compared to no treatment (these data are not shown).
2. 5HT1B receptor. Treatment with the antagonist methysergide had a concentration-dependent effect on the 5HT1B-NLS serotonin receptor. A maximum effect for cell surface receptor retention of 11-fold was obtained at 5 µM; there was also a 10fold increase at 1 µM and a 9-fold increase at 50 nM in cell surface receptor (Fig. 5A) . A similar effectiveness to retain the 5HT1B-NLS receptor on the cell surface was obtained with antagonist SB 224489; at 1 µM concentration, there was a 12-fold increase in cell surface receptor.
Serotonin displayed a concentration-dependent ability to retain cell surface receptor (Fig. 5B) . At 5 µM, a maximum effect of 11.5-fold was obtained; there was a 10.8-fold increase at 1 µM and a 6.4-fold increase at 50 nM in cell surface receptor density.
Cells expressing 5HT1B-NLS were initially treated with serotonin for 24 h, and then serotonin was replaced with methysergide (from 1-500 nM). It is notable that 10 to 50 nM methysergide was more effective (14-fold) than the direct application of 500 nM serotonin (9 .5-fold, Fig. 5C ). Without the serotonin treatment, the receptor will leave the cell surface ( Fig. 5C , "5HT wash-off" bar).
3. 5HT1A receptor. The serotonin 5HT1A receptor also translocated robustly off the cell surface when the NLS was incorporated in helix 8. At 5 µM of methysergide, a maximum effect of 14-fold was obtained, whereas there was a 12.5-fold increase at 1 µM and a 5-fold increase at 50 nM in 5HT1A-NLS receptor cell surface density (Fig. 6A) .
Serotonin also had a concentration-dependent effect to retain the receptor on the cell surface. There was an 8-fold increase at 1 µM treatment and a 4-fold increase at 50 nM (Fig. 6B) , an effect similar to that observed with 5HT1B receptor.
µ-Opioid receptor.
The opioid antagonist naloxone retained the peptidergic opioid µ-NLS receptor on the cell surface. At 10 µM concentration of naloxone, there was a 9.5-fold increase in the cell surface density of the µ-NLS receptor compared to cells with no treatment, and at 1 µM concentration, there was an 8-fold increase (Fig. 7A) . The peptide agonist DAMGO also retained the µ-NLS receptor on the cell surface. At 5 µM concentration of drug, there was a 10-fold increase in cell surface receptor density compared to control cells with no treatment, and at 1 µM concentration of DAMGO, there was an 8-fold increase (Fig. 7B) .
The opioid agonist morphine effectively retained the opioid µ-NLS receptor on the cell surface. There was a 5-fold increase at 1 µM concentration of morphine treatment and a 4-fold increase with 1 nM in the cell surface density receptor compared with no treatment (data not shown).
M1 muscarinic receptor.
The cholinergic antagonist ipratropium bromide induced a concentration-dependent retention of the M1-NLS receptor on the cell surface ( Fig. 8A) . There was a maximum effect of a 15-fold increase at 5 µM concentration of drug, a 13.5-fold increase at 1 µM, and an 8-fold increase at 50 nM in cell surface receptor density.
A concentration-dependent effect of the antagonist pirenzepine also indicated the ability to retain the M1-NLS receptor on the cell surface. There was a 6-fold increase at 5 µM concentration and a 5-fold increase at 1 µM in cell surface receptor (Fig. 8B) . 6. β 2-adrenergic receptor. A concentration-dependent effect of the agonist isoproternol indicated the ability to retain the β2-adrenergic-NLS receptor (β2-AR-NLS) on the cell surface ( Fig. 8C) . At 5 µM concentration of the drug, there was a 14-fold increase, and at 1 µM, there was an 11.8-fold increase in cell surface receptor density compared to no treatment. Treatments with the dopamine antagonists raclopride and SCH 23390 had no effect on β2-AR-NLS receptor density.
A dose-dependent effect of the antagonist propranolol also indicated the ability to retain the adrenergic receptor on the cell surface. At 5 µM concentration, there was a 9-fold increase, and at 1 µM, there was an 8-fold increase in cell surface receptor (Fig. 8D) .
DISCUSSION
A priority was to develop a cell-based assay for GPCRs that could enable discovery of therapeutically valuable compounds. The method now described is uniquely capable of identifying either antagonist or agonist compounds on a primary screen of GPCRs. As validated now for 7 different receptors, we developed an assay with significant advantages. By integrating the established EFC methodology with the unique GPCR-NLS technology, we have available an efficient technology suitable for high-throughput applications. The quantitative properties, combined with the sensitivity of EFC detection, ensured that the strategy is easy to use and provides a virtually addition-only assay protocol as required for HTS.
In the multiple receptor examples provided, we have shown that the GPCR-NLS assay provided an amplified response for each GPCR localized to the cell surface, allowing for a sensitive detection assay of receptor retained at the cell surface. This assay was successfully formatted for HTS in 96-well plates. The technology demonstrated versatility with respect to the receptor detection systems employed, using visualizationbased fluorescence microscopy to evaluate the extent of receptor translocation to the nucleus or the EFC strategy to quantify receptor retention on the cell surface.
The D1 dopamine receptor interacting compounds demonstrated concentration-dependent responses at nanomolar concentrations. Stereoselectivity was demonstrated by the lack of effect of (-)BTC, and specificity was shown by lack of effect of βadrenergic and D2 receptor antagonists on D1-NLS translocation. Data from each of the other GPCR-NLSs-D5 dopamine, serotonin 5HT1B and 5HT1A, µ-opioid, M1 muscarinic, and β2-adrenergic receptors-all validated the results obtained with D1-NLS. The results demonstrated the efficacy of the strategy for receptors that couple to a range of endogenous G-proteins, such as Gs (D1 and D5 dopamine), Golf (D1 dopamine), Gi (serotonin 5HT1B, 5HT1A, µ-opioid), and Gq (D5 dopamine, M1 muscarinic) proteins. The assay also demonstrated effectiveness for GPCRs that interact with different endogenous ligands, including monoamines and peptides. This assay does not require any prior knowledge of the natural effector system or secondmessenger linkage of the GPCR, unlike most GPCR drug discovery assays. Each of these properties of the assay makes it the most suitable assay for screening compounds targeting orphan GPCRs. This technology can also be employed to screen known GPCRs to identify novel ligands, and it is not dependent on a normal physiological functional response of the receptor.
Many cell-based assays detect changes in levels of second messengers induced by agonist activation of GPCRs. These approaches, such as measuring cAMP, can only detect activation
